PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions
2026-01-12 · Cancers 2026;18(2):234
Publicaties
Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report
2026-01-02 · Eur J Nucl Med Mol Imaging 2026;53(2):1113-1116
68Ga-PSMA-11 PET/CT for Initial Staging of Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Predicts Overall Survival: An IAEA Multicenter Study
2026-01-29 · J Nucl Med 2026, online ahead of print
Feasibility of [89Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer
2026-01-29 · J Nucl Med 2026, online ahead of print
Identification of Aldosterone-Producing Adrenal Adenomas Using [68Ga]Ga-Pentixafor PET/CT in an Australian Cohort
2026-01-29 · J Nucl Med 2026, online ahead of print
Predicting the unpredictable: prognostic and predictive power of FAPI-PET imaging in oncology: a systematic review and meta-analysis
2026-01-27 · Eur J Nucl Med Mol Imaging 2026, online ahead of print
PET-Based Outcome Prediction in Patients with Prostate Cancer Scheduled for [225Ac]Ac-PSMA Radiopharmaceutical Therapy
2026-02-05 · J Nucl Med 2026, online ahead of print
Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer
2026-02-15 · Eur J Nucl Med Mol Imaging 2026;53:1913-1926
Diagnostic Efficacy of FAPI-PET/CT Versus [18F]FDG-PET/CT in Upper-Abdominal Malignancies: A Systematic Review and Meta-Analysis
2026-02-09 · Diagnostics (Basel) 2026;16(4):520
Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions
2026-02-20 · Eur J Nucl Med Mol Imaging 2026;53:1419-1433
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
2026-03-01 · Nat Cancer 2026
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial
2026-03-15 · J Nucl Med 2026, online ahead of print
CD70-Targeted Immuno-PET/CT for Detecting Heterogeneous CD70 Expression in Lymphomas: A Pilot Clinical Study
2026-03-10 · J Nucl Med 2026
Efficacy of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Carcinoma: A Systematic Review and Meta-analysis
2026-03-20 · J Nucl Med 2026, online ahead of print
Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors
2026-04-10 · J Nucl Med 2026
[68Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[18F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study
2026-04-05 · J Nucl Med 2026
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease
2026-04-12 · J Nucl Med 2026
PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology
2026-04-18 · J Nucl Med 2026
Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study
2026-04-25 · J Nucl Med 2026
Nonmalignant findings on FAPI PET: An updated rapid systematic review of the literature
2026-04-15 · Semin Nucl Med 2026
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
2025-05-01 · J Nucl Med 2025 May;66(5):665-672
Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
2025-07-24 · Eur J Nucl Med Mol Imaging 2025 Dec;53(1):93-104
Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI
2025-04-01 · Eur J Nucl Med Mol Imaging 2025 Apr;52(5):1658-1670
Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy
2025-06-01 · Eur J Nucl Med Mol Imaging 2025 Jun;52(7):2335-2342
External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer
2025-08-01 · Eur J Nucl Med Mol Imaging 2025 Aug;52(10):3744-3756
Practical Overview of 123I-Ioflupane Imaging in Parkinsonian Syndromes
2024-02-01 · RadioGraphics 2024 Feb;44(2):e230102
Drug-Induced Parkinsonism or Parkinson's Disease: A Diagnostic Challenge in a Psychiatric Patient
2025-07-17 · Cureus 2025 Jul 17;17(7):e88177
DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker
2020-06-01 · JACC Cardiovasc Imaging 2020 Jun;13(6):1353-1363
Cerebellar cortical amyloid deposition biases 18F-Florbetapir PET quantification with whole cerebellum as reference region.
2026-09-17 · Eur J Nucl Med Mol Imaging
Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis.
2026-09-17 · Eur J Nucl Med Mol Imaging
Referentie-inhoud van de oorspronkelijke site. Datums en statussen volgen de bronnen; er is geen nieuwe wetenschappelijke controle uitgevoerd.
De centrumgids bekijken